MAX dimerization protein 3Genealiases: BHLHC13 · MAD3 · MYX
Q-omics provides the consensus-scored MXD3 profile across patient tissues and cancer cell-line models. MXD3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MXD3 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, MXD3 RNA expression shows 18,337 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, and ACC as cancer lineages where MXD3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MXD3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MXD3 survival associations across molecular data types. MXD3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MXD3 RNA expression–survival associations across cancer types. High MXD3 expression shows unfavorable associations in KIRC, ACC, KICH, LIHC, UVM and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MXD3 RNA expression.
This table summarizes MXD3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MXD3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MXD3 shows higher tumor expression in KIRC, KIRP, COAD, BLCA, LIHC and LUAD. The KIRC box plot shows higher MXD3 RNA expression in tumor versus normal tissue (log2 FC = +1.075, t-test p < 0.001).
This table shows molecular features associated with MXD3 in patient tissues and cancer cell lines. In patient samples, MXD3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MXD3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
